Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG439E)

Drug Name

Fipamezole Drug Info

Synonyms

Fipamezole; 150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2	[1]

Cross-matching ID

PubChem CID: 213041
CAS Number: CAS 150586-58-6
TTD Drug ID: DMG439E

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adrenergic receptor Alpha-2 (ADRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
Meperidine	DMX4GND	Pain	MG30-MG3Z	Approved	[4]
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[5]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[3]
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[6]
Dexmedetomidine	DM93L4X	Irritability	MB24	Approved	[7]
Yohimbine	DMJCP1Y	Erectile dysfunction	HA01.1	Approved	[8]
Guanabenz	DM5QWEL	High blood pressure	BA00	Approved	[9]
Tizanidine	DMR2IQ4	Spasm	MB47.3	Approved	[10]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00559871) Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease. U.S. National Institutes of Health.
2	Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
3	Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
4	Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
5	Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
6	Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
7	Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
8	Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
9	Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
10	Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
11	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.